An Unusual Case of Delayed-Onset Rituximab-Induced Ventricular Tachycardia: A Case Report.

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL
Gevorg Arabyan, Raphi Hambartzhumian, Anthony Martin Lim, Marrey Quizon, Julia Oberndorf, Jonathan Abaya Ghazaleh, Dinesh Sharma
{"title":"An Unusual Case of Delayed-Onset Rituximab-Induced Ventricular Tachycardia: A Case Report.","authors":"Gevorg Arabyan, Raphi Hambartzhumian, Anthony Martin Lim, Marrey Quizon, Julia Oberndorf, Jonathan Abaya Ghazaleh, Dinesh Sharma","doi":"10.1177/23247096241255813","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiac disease associated with cancer treatment is a common adverse effect that is well-treated with appropriate monitoring. However, some cardiac adverse effects with cancer treatment are not well-understood, in particular rituximab-associated ventricular tachycardia. We present the fourth case of rituximab-associated ventricular tachycardia in a patient who is rituximab-naive and who does not have known cardiac disease history. This patient developed non-sustained polymorphic ventricular tachycardia 14 hours after rituximab was started and 6 hours after it was stopped, and after extensive monitoring including a 30-day event monitor, did not develop further significant runs of ventricular tachycardia.</p>","PeriodicalId":16198,"journal":{"name":"Journal of investigative medicine high impact case reports","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11107307/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of investigative medicine high impact case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23247096241255813","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Cardiac disease associated with cancer treatment is a common adverse effect that is well-treated with appropriate monitoring. However, some cardiac adverse effects with cancer treatment are not well-understood, in particular rituximab-associated ventricular tachycardia. We present the fourth case of rituximab-associated ventricular tachycardia in a patient who is rituximab-naive and who does not have known cardiac disease history. This patient developed non-sustained polymorphic ventricular tachycardia 14 hours after rituximab was started and 6 hours after it was stopped, and after extensive monitoring including a 30-day event monitor, did not develop further significant runs of ventricular tachycardia.

迟发性利妥昔单抗诱发室性心动过速的罕见病例:病例报告。
与癌症治疗相关的心脏病是一种常见的不良反应,通过适当的监测可以得到很好的治疗。然而,人们对癌症治疗的一些心脏不良反应并不十分了解,尤其是利妥昔单抗相关性室性心动过速。我们介绍了第四例利妥昔单抗相关性室性心动过速病例,患者对利妥昔单抗无免疫反应,也没有已知的心脏病史。该患者在开始使用利妥昔单抗 14 小时后和停药 6 小时后出现非持续性多形性室性心动过速,经过包括 30 天事件监测在内的广泛监测后,没有再出现明显的室性心动过速。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
165
审稿时长
12 weeks
期刊介绍: The AFMR is committed to enhancing the training and career development of our members and to furthering its mission to facilitate the conduct of research to improve medical care. Case reports represent an important avenue for trainees (interns, residents, and fellows) and early-stage faculty to demonstrate productive, scholarly activity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信